Pemetrexed Dipotassium Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 100 mg, 500 mg
Reference Brands: Alimta (USA), Pemfexy (USA)
Category:
Oncology Cancer Care
Pemetrexed dipotassium is available in Injection
and strengths such as 100 mg, 500 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Pemetrexed dipotassium is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Pemetrexed dipotassium can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Pemetrexed dipotassium, marketed under brand names such as Alimta, is a chemotherapy medication used for the treatment of malignant pleural mesothelioma and non-small cell lung cancer (NSCLC). It is particularly indicated for the treatment of unresectable pleural mesothelioma, often in combination with cisplatin, for patients who are not candidates for curative surgery. Pemetrexed interferes with folate-dependent metabolic processes, inhibiting the synthesis of DNA, RNA, and proteins in rapidly dividing cancer cells, thereby slowing tumor growth and inducing cell death. In non-small cell lung cancer, Pemetrexed is approved as a first-line therapy in combination with cisplatin for locally advanced or metastatic disease, as well as for maintenance therapy in patients showing response to initial treatment. Its targeted action against rapidly proliferating cells makes it an effective option in oncology, providing a clinically established approach for managing these aggressive cancers. Pemetrexed is administered intravenously under professional supervision and can be used alone or in combination with other chemotherapeutic agents to enhance therapeutic efficacy. Its widespread use and proven effectiveness have made it a cornerstone in the management of pleural mesothelioma and non-squamous NSCLC.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing